177 related articles for article (PubMed ID: 35138911)
21. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers.
Walseng E; Wang B; Yang C; Patel P; Zhao C; Zhang H; Zhao P; Mazor Y
Front Immunol; 2023; 14():1275304. PubMed ID: 38022650
[TBL] [Abstract][Full Text] [Related]
22. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
Morton LT; Reijmers RM; Wouters AK; Kweekel C; Remst DFG; Pothast CR; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2020 Jan; 28(1):64-74. PubMed ID: 31636040
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
[TBL] [Abstract][Full Text] [Related]
25. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.
Provasi E; Genovese P; Lombardo A; Magnani Z; Liu PQ; Reik A; Chu V; Paschon DE; Zhang L; Kuball J; Camisa B; Bondanza A; Casorati G; Ponzoni M; Ciceri F; Bordignon C; Greenberg PD; Holmes MC; Gregory PD; Naldini L; Bonini C
Nat Med; 2012 May; 18(5):807-815. PubMed ID: 22466705
[TBL] [Abstract][Full Text] [Related]
26. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
[TBL] [Abstract][Full Text] [Related]
27. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
Xue SA; Gao L; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; Uckert W; Morris E; Stauss H
Blood; 2005 Nov; 106(9):3062-7. PubMed ID: 16020516
[TBL] [Abstract][Full Text] [Related]
28. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
29. Features of the TCR repertoire associate with patients' clinical and molecular characteristics in acute myeloid leukemia.
Pospiech M; Tamizharasan M; Wei YC; Kumar AMS; Lou M; Milstein J; Alachkar H
Front Immunol; 2023; 14():1236514. PubMed ID: 37928542
[TBL] [Abstract][Full Text] [Related]
30. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
[TBL] [Abstract][Full Text] [Related]
32. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
33.
Bonte S; de Munter S; Billiet L; Goetgeluk G; Ingels J; Jansen H; Pille M; de Cock L; Weening K; Taghon T; Leclercq G; Vandekerckhove B; Kerre T
Oncoimmunology; 2021; 10(1):1954800. PubMed ID: 34367734
[TBL] [Abstract][Full Text] [Related]
34. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
[TBL] [Abstract][Full Text] [Related]
35. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
[TBL] [Abstract][Full Text] [Related]
36. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG; Egan DN; Bar M; Schmitt TM; McAfee MS; Paulson KG; Voillet V; Gottardo R; Ragnarsson GB; Bleakley M; Yeung CC; Muhlhauser P; Nguyen HN; Kropp LA; Castelli L; Wagener F; Hunter D; Lindberg M; Cohen K; Seese A; McElrath MJ; Duerkopp N; Gooley TA; Greenberg PD
Nat Med; 2019 Jul; 25(7):1064-1072. PubMed ID: 31235963
[TBL] [Abstract][Full Text] [Related]
37. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
[TBL] [Abstract][Full Text] [Related]
38. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
39. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]